Impact of HER2 on Prognosis and Benefit from Adjuvant Chemotherapy in Stage II/III Gastric Cancer Patients: a Multicenter Observational Study
Xianchun Gao,Lulu Zhao,Nannan Zhang,Weili Han,Kun Liu,Junya Yan,Ling Chen,Yan Pan,Renlong Li,Wenjiao Li,Haohao Zhang,Hongwei Li,Shibo Wang,Xiaoliang Gao,Penghui Niu,Wanqing Wang,Gang Ji,Qingchuan Zhao,Yuanyuan Lu,Zengshan Li,Lei Shang,Han Liang,Kaichun Wu,Jingyu Deng,Yingtai Chen,Yongzhan Nie
DOI: https://doi.org/10.1097/js9.0000000000000370
2023-01-01
International Journal of Surgery
Abstract:Background: Human epidermal growth factor receptor 2 (HER2) is a well-developed therapeutic target in breast and gastric cancer (GC). However, the impact of HER2 on survival and benefit from fluorouracil-based adjuvant chemotherapy remains unclear in patients with GC. Materials and Methods: This multicenter cohort study involved 5622 consecutive stage II/III GC patients. HER2 expression was assessed prospectively via immunohistochemistry (IHC). The staining intensity was graded on a scale of 0 to 3+. An IHC score of 2+or 3+was defined as high expression, and a score of 3+was defined as overexpression. Results: HER2 overexpression was independently associated with a lower 5-year overall survival (OS) in stage II [hazard ratio (HR), 2.10; 95% CI: 1.41–3.11], but not in stage III GC (HR, 1.00; 95% CI, 0.82–1.20). Further analysis revealed that stage II patients with high HER2 expression showed a poorer response to chemotherapy than stage II patients with low HER2 expression (P interaction=0.024). The HRs for 5-year OS were 0.51 (95% CI, 0.38–0.70) for stage II patients with low HER2 expression, 0.58 (95% CI, 0.51–0.66) for stage III patients with low HER2 expression, 1.13 (95% CI, 0.61–2.09) for stage II patients with high HER2 expression, and 0.47 (95% CI, 0.36–0.61) for stage III patients with high HER2 expression. Conclusions: Fluorouracil-based adjuvant chemotherapy is insufficient for stage II GC patients with high HER2 expression, indicating that prospective trials are required to validate alternative HER2-targeted adjuvant therapies in the individuals above.